Taselisib

N/A

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameTaselisib
Drug Alias Name他司利塞Taselisibum他塞利司RG-7604GDC-0032 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase gamma inhibitors +[4] 
TargetsPhosphatidylinositol 3 kinase betaPhosphatidylinositol 3 kinase alphaPhosphatidylinositol-4,5-Bisphosphate 3 kinase gamma +[4] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[32] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[39] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe Netherlands Cancer InstituteF. Hoffmann-La Roche AgF. Hoffmann-La Roche Ltd +[6] 
Inactive CompaniesRoche Pharma Ag
Active IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[28] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast NeoplasmsCarcinoma, Squamous Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A